Stoke Therapeutics (NASDAQ:STOK) Now Covered by Analysts at Chardan Capital

Chardan Capital started coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note released on Friday, MarketBeat reports. The brokerage issued a buy rating and a $24.00 target price on the stock.

STOK has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Leerink Partners began coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Stock Up 3.4 %

Shares of NASDAQ:STOK opened at $11.68 on Friday. Stoke Therapeutics has a 52-week low of $4.09 and a 52-week high of $17.58. The company has a market capitalization of $618.65 million, a price-to-earnings ratio of -5.56 and a beta of 0.95. The company has a 50 day moving average of $12.48 and a two-hundred day moving average of $13.55.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. On average, equities analysts anticipate that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, CEO Edward M. Md Kaye sold 6,170 shares of the business’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $78,852.60. Following the sale, the chief executive officer now owns 68,671 shares of the company’s stock, valued at approximately $877,615.38. The trade was a 8.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the transaction, the insider now directly owns 51,277 shares of the company’s stock, valued at $618,913.39. This represents a 16.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock valued at $809,421 in the last quarter. Corporate insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of STOK. Quest Partners LLC acquired a new position in shares of Stoke Therapeutics in the 2nd quarter worth approximately $29,000. Nisa Investment Advisors LLC boosted its holdings in Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after buying an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stoke Therapeutics in the second quarter worth approximately $123,000. Intech Investment Management LLC bought a new position in shares of Stoke Therapeutics in the third quarter valued at $160,000. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.